Not Before Time, England Announces Conditional Reimbursement Plans
This article was originally published in Scrip
Executive Summary
Better late than never: the consultation on what happens next after England's Cancer Drugs Fund finishes on March 31, 2016 is finally out. NHS England and NICE, England's HTA body, have together published proposals that include the conditional reimbursement of promising drugs that under the old system would likely have been thwarted by uncertainties in the evidence supporting them.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.